Geographic Expansion Onyx Scientific has been expanding its manufacturing footprint with UK and Northern Europe facilities and recent capacity growth at the UK site, presenting opportunities to position as a preferred provider for European-based clinical and commercial API production.

US Growth Dedicated leadership in North America and ongoing expansion of commercial operations in the United States signal a readiness to engage pharma and biotech partners seeking early access to scalable API manufacturing and process development in the US market.

Full-service CDMO Serving from discovery through Phase III and into commercial scale, including GMP API synthesis, process development, solid-state chemistry, and tech transfer capability, enabling cross-division partnerships and end-to-end outsourcing deals.

Regulatory Stronghold MHRA and FDA licensed sites provide credibility for global clients requiring compliant manufacturing at scale, supporting risk reduction in outsourcing decisions and facilitating entry for complex medicinal chemistry programs.

Mid-market Focus With a revenue range indicative of small to mid-sized projects and a lean organization, Onyx Scientific is well-positioned for collaboration with mid-tier pharma/biotech companies seeking agile, cost-effective API development and manufacturing partnerships.